CXCL2, a new critical factor and therapeutic target for cardiovascular diseases

• Published in: Clinical and experimental hypertension (1993) Vol. 42; no. 5; pp. 428 - 437
• Main Authors: Guo, Lin-Ya, Yang, Fang, Peng, Li-Jun, Li, Yan-Bing, Wang, Ai-Ping
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 03.07.2020; Taylor & Francis Group
• Subjects: atherosclerosis; cardiovascular disease; CXCL2; inflammation; atherosclerosis; cardiovascular disease; inflammation; CXCL2
• ISSN: 1064-1963; 1525-6006; 1525-6006
• DOI: 10.1080/10641963.2019.1693585

Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Previous studies have shown that inflammatory chemokines are involved in the physiological functions of cytoskeletal reorganization, cell migration, adhesion and immune responses. However, in the past decade, there have been studies showing that inflammatory chemokines play a key role in CVD. Importantly, CXC motif chemokine ligand 2 (CXCL2) has been shown to be involved in the pathogenesis of cardiovascular disease. CXCL2 exerts its effects on the cardiovascular system by mediating inflammatory responses, but the specific signaling pathways by which CXCL2 exerts its effects in CVD remain unknown and need to be further investigated. This review aims to investigate the expression changes of CXCL2 in acute myocardial infarction (AMI), atherosclerosis (AS), obesity, diabetes and ischemic stroke (IS) and its potential key role in cardiovascular disease in order to provide new ideas for the prevention and treatment of cardiovascular diseases.